Sevelamer
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
| Clinical data | |
|---|---|
| Pronunciation | (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) |
| Trade names | Renagel, Renvela |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601248 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 0% |
| Excretion | Feces 100% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | [(C3H7N)a+b.(C9H17N2O)c]m where a+b:c = 9:1 |
| Molar mass | variable |
| (what is this?) (verify) | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.